Local delivery of therapeutics for percutaneous coronary intervention

Current Drug Delivery

Volumn 8, Issue 5, 2011, Pages 534-556

  Kennedy, Karen L ^a   Lucas, Alexandra R ^b   Wan, Wankei ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angioplasty; Balloon catheters; Controlled release; Drug delivery; Drug eluting stents; Percutaneous coronary intervention; Restenosis

Indexed keywords

ABCIXIMAB; ANGIOPEPTIN; ANTITHROMBOCYTIC AGENT; ARGATROBAN; ARGININE; BATIMASTAT; CD34 ANTIBODY; DEXAMETHASONE; DIMETHYL SULFOXIDE; ESTRADIOL; EVEROLIMUS; HEPARIN; LEFLUNOMIDE; MYCOPHENOLIC ACID; NANOPARTICLE; NITRIC OXIDE DONOR; PACLITAXEL; POLYMER; POLYVINYL ALCOHOL; PROTEIN SERP 1; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; ZOTAROLIMUS;

BALLOON CATHETER; BIOCOMPATIBILITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED DRUG RELEASE; CORONARY ARTERY DISEASE; CORONARY STENT; CROSS LINKING; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; HUMAN; HYDROGEL; NEOINTIMA; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN SECRETION; RESTENOSIS; REVIEW; THROMBOSIS; THROMBUS; VASCULAR ENDOTHELIUM;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS;

EID: 80051725786     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720111796642282     Document Type: Review

References (215)

1. Gershlick, A.H. Treating atherosclerosis: local drug delivery from laboratory studies to clinical trials. Atherosclerosis, 2002, 160(2), 259-271.
2. Brown, D.A.; Lee, E.W.; Loh, C.T.; Kee, S.T. A New Wave in Treatment of Vascular Occlusive Disease: Biodegradable Stents- Clinical Experience and Scientific Principles. J. Vasc. Interv. Radiol., 2009, 20(3), 315-324.
3. Rajagopal, V.; Rockson, S.G. Coronary restenosis: A review of mechanisms and management. Am. J. Med., 2003, 115(7), 547-553.
4. Kraitzer, A.; Kloog, Y.; Zilberman, M. Approaches for prevention of restenosis. J. Biomed. Mater. Res. Part B, 2008, 85B(2), 583-603.
5. Welt, F.G.P.; Rogers, C. Inflammation and restenosis in the stent era. Arterioscler. Thromb. Vasc. Biol., 2002, 22(11), 1769-1776.
6. Califf, R.M.; Fortin, D.F.; Frid, D.J.; Harlan, W.R.; Ohman, E.M.; Bengtson, J.R.; Nelson, C.L.; Tcheng, J.E.; Mark, D.B.; Stack, R.S. Restenosis after coronary angioplasty - an overview. J. Am. Coll. Cardiol., 1991, 17(6), B2-B13.
7. Bauriedel, G.; Schmucking, I.; Schmidt, T.; Braun, P.; Park, J.W.; Heinrich, K.W.; Luderitz, B. Intimal cell density in postangioplasty versus primary coronary and peripheral lesions: A systematic study on human atherectomy samples. J. Interv. Cardiol., 1997, 10(6), 417-425.
8. Finn, A.V.; Nakazawa, G.; Joner, M.; Kolodgie, F.D.; Mont, E.K.; Gold, H.K.; Virmani, R. Vascular responses to drug eluting stents - Importance of delayed healing. Arterioscler. Thromb. Vasc. Biol., 2007, 27(7), 1500-1510.
9. Woods, T.C.; Marks, A.R. Drug-eluting stents. Annu. Rev. Med., 2004, 55, 169-178.
10. Burt, H.M.; Hunter, W.L. Drug-eluting stents: A multidisciplinary success story. Adv. Drug Deliv. Rev., 2006, 58(3), 350-357.
11. Pendyala, L.; Jabara, R.; Robinson, K.; Chronos, N. Passive and active polymer coatings for intracoronary stents: novel devices to promote arterial healing. J. Interv. Cardiol., 2009, 22(1), 37-48.
12. Tesfamariam, B. Local vascular toxicokinetics of stent-based drug delivery. Toxicol. Lett., 2007, 168(2), 93-102.
13. Tesfamariam, B. Drug release kinetics from stent device-based delivery systems. J. Cardiovasc. Pharmacol., 2008, 51(2), 118-125.
14. Schwartz, R.S.; Chronos, N.A.; Virmani, R. Preclinical restenosis models and drug-eluting stents - Still important, still much to learn. J. Am. Coll. Cardiol., 2004, 44(7), 1373-1385.
15. Farb, A.; Kolodgie, F.D.; Hwang, J.Y.; Burke, A.P.; Tefera, K.; Weber, D.K.; Wight, T.N.; Virmani, R. Extracellular matrix changes in stented human coronary arteries. Circulation, 2004, 110(8), 940-947.
16. Scott, N.A. Restenosis following implantation of bare metal coronary stents: Pathophysiology and pathways involved in the vascular response to injury. Adv. Drug Deliv. Rev., 2006, 58(3), 358-376.
17. Rogers, C.; Welt, F.G.P.; Karnovsky, M.J.; Edelman, E.R. Monocyte recruitment and neointimal hyperplasia in rabbits - Coupled inhibitory effects of heparin. Arterioscler. Thromb. Vasc. Biol., 1996, 16(10), 1312-1318.
18. Mizuno, O.; Ikeda, U.; Hojo, Y.; Fujikawa, H.; Katsuki, T.; Shimada, K. Tissue factor expression in coronary circulation as a prognostic factor for late restenosis after coronary angioplasty. Cardiology, 2001, 95(2), 84-89.
19. Strauss, B.H.; Lau, H.K.; Bowman, K.A.; Sparkes, J.; Chisholm, R.J.; Garvey, M.B.; Fenkell, L.L.; Natarajan, M.K.; Singh, I.; Teitel, J.M. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation, 1999, 100(15), 1616-1622.
20. Park, D.; Yun, S.; Lee, J.; Kim, W.; Kang, S.; Lee, S.; Kim, Y.; Lee, C.W.; Kim, J.; Park, S.; Park, S. C-Reactive protein and the risk of stent thrombosis and cardiovascular events after drugeluting stent implantation. Circulation, 2009, 120(20), 1987-1995.
21. Pickering, J.G.; Weir, L.; Jekanowski, J.; Kearney, M.A.; Isner, J.M. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revascularization. J. Clin. Invest., 1993, 91(4), 1469-1480.
22. Obrien, E.R.; Alpers, C.E.; Stewart, D.K.; Ferguson, M.; Tran, N.; Gordon, D.; Benditt, E.P.; Hinohara, T.; Simpson, J.B.; Schwartz, S.M. Proliferation in primary and restenotic coronary atherectomy tissue - implications for antiproliferative therapy. Circ. Res., 1993, 73(2), 223-231.
23. Glover, C.; Ma, X.L.; Chen, Y.X.; Miller, H.; Veinot, J.; Labinaz, M.; O'Brien, E. Human in-stent restenosis tissue obtained by means of coronary atherectomy consists of an abundant proteoglycan matrix with a paucity of cell proliferation. Am. Heart J., 2002, 144(4), 702-709.
24. Chung, I.M.; Gold, H.K.; Schwartz, S.M.; Ikari, Y.; Reidy, M.A.; Wight, T.N. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J. Am. Coll. Cardiol., 2002, 40(12), 2072-2081.
25. Kavanagh, C.A.; Rochev, Y.A.; Gallagher, W.A.; Dawson, K.A.; Keenan, A.K. Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems. Pharmacol. Ther., 2004, 102(1), 1-15.
26. Sousa, J.E.; Serruys, P.W.; Costa, M.A. New frontiers in cardiology - Drug-eluting stents: Part I. Circulation, 2003, 107(17), 2274-2279.
27. Hoffmann, R.; Mintz, G.S.; Dussaillant, G.R.; Popma, J.J.; Pichard, A.D.; Satler, L.F.; Kent, K.M.; Griffin, J.; Leon, M.B. Patterns and mechanisms of in-stent restenosis - A serial intravascular ultrasound study. Circulation, 1996, 94(6), 1247-1254
28. Acharya, G.; Park, K. Mechanisms of controlled drug release from drug-eluting stents. Adv. Drug Deliv. Rev., 2006, 58(3), 387-401.
29. van der Hoeven, B.L.; Pires, N.M.M.; Warda, H.M.; Oemrawsingh, P.V.; van Vlijmen, B.J.M.; Quax, P.H.A.; Schalij, M.J.; van der Wall, E.E.; Jukema, J.W. Drug-eluting stents: results, promises and problems. Int. J. Cardiol., 2005, 99(1), 9-17.
30. Kocsis, J.F.; Llanos, G.; Holmer, E. Heparin-coated stents. J. Long. Term. Eff. Med., 2000, 10(1-2), 19-45.
31. Marx, S.O.; Marks, A.R. Bench to bedside - The development of rapamycin and its application to stent restenosis. Circulation, 2001, 104(8), 852-855.
32. Rowinsky, E.K.; Donehower, R.C. Drug-Therapy - Paclitaxel (Taxol). N. Engl. J. Med., 1995, 332(15), 1004-1014.
33. Blagosklonny, M.V.; Darzynkiewicz, Z.; Halicka, H.D.; Pozarowski, P.; Demidenko, Z.N.; Barry, J.J.; Kamath, K.R.; Herrmann, R.A. Paclitaxel induces primary and postmitotic G(1) arrest in human arterial smooth muscle cells. Cell Cycle, 2004, 3(8), 1050-1056.
34. Parry, T.J.; Brosius, R.; Thyagarajan, R.; Carter, D.; Argentieri, D.; Falotico, R.; Siekierka, J. Drug-eluting stents: Sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur. J. Pharmacol., 2005, 524(1-3), 19-29.
35. Sousa, J.E.; Serruys, P.W.; Costa, M.A. New frontiers in cardiology - Drug-eluting stents: Part II. Circulation, 2003, 107(18), 2383-2389.
36. Serruys, P.W.; van Hout, B.; Bonnier, H.; Legrand, V.; Garcia, E.; Macaya, C.; Sousa, E.; van der Giessen, W.; Colombo, A.; Seabra- Gomes, R.; Kiemeneij, F.; Ruygrok, P.; Ormiston, J.; Emanuelsson, H.; Fajadet, J.; Haude, M.; Klugmann, S.; Morel, M.A.; Benestent Study Grp. Randomised comparison of implantation of heparincoated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet, 1998, 352(9129), 673-681.
37. Serruys, P.; Grines, C.; Stone, G.; Garcia, E.; Kiemeney, F.; Morice, M.; Sousa, J.; Hamm, C.; Costantini, C.; Probst, P.; Rutsch, W.; Penn, I.; Fernandez-Aviles, F.; Vandormael, M.; Bartorelli, A.; Bilodeau, L.; Eijgelshoven, M. Stent implantation in acute myocardial infarction using a heparin-coated stent: a pilot study as a preamble to a randomized trial comparing balloon angioplasty and stenting. Inter. J. Cardiovasc. Interv., 1998, 1(1), 19-27.
38. Buller, C.E.; Dzavik, V.; Carere, R.G.; Mancini, G.B.J.; Barbeau, G.; Lazzam, C.; Anderson, T.J.; Knudtson, M.L.; Marquis, J.F.; Suzuki, T.; Cohen, E.A.; Fox, R.S.; Teo, K.K.; TOSCA Investigators. Primary stenting versus balloon angioplasty in occluded coronary arteries - The total occlusion study of Canada (TOSCA). Circulation, 1999, 100(3), 236-242.
39. Camenzind, E.; Kint, P.P.; Di Mario, C.; Ligthart, J.; van der Giessen, W.; Boersma, E.; Serruys, P.W. Intracoronary heparin delivery in humans. Acute feasibility and long-term results. Circulation, 1995, 92(9), 2463-2472.
40. Mckay, R.G.; Fram, D.B.; Hirst, J.A.; Kiernan, F.J.; Primiano, C.A.; Rinaldi, M.J.; Azrin, M.A.; Mitchel, J.F.; Waters, D.D. Treatment of intracoronary thrombus with local urokinase infusion using a new, site-specific drug-delivery system - the dispatch(tm) catheter. Cathet. Cardiovasc. Diagn., 1994, 33(2), 181-188.
41. Itoh, T.; Nonogi, H.; Miyazaki, S.; Itoh, A.; Daikoku, S.; Morii, I.; Goto, Y.; 3D-CAT investigators. Local delivery of argatroban for the prevention of restenosis after coronary balloon angioplasty - A prospective randomized pilot study. Circ. J., 2004, 68(7), 615-622.
42. Bartorelli, A.L.; Trabattoni, D.; Galli, S.; Grancini, L.; Cozzi, S.; Ravagnani, P. Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA. Catheter. Cardiovasc. Interv., 1999, 48(2), 211-213.
43. Gershlick, A.; De Scheerder, I.; Chevalier, B.; Stephens-Lloyd, A.; Camenzind, E.; Vrints, C.; Reifart, N.; Missault, L.; Goy, J.J.; Brinker, J.A.; Raizner, A.E.; Urban, P.; Heldman, A.W. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent - The European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation, 2004, 109(4), 487-493.
44. Hong, M.K.; Mintz, G.S.; Lee, C.W.; Song, J.M.; Han, K.H.; Kang, D.H.; Song, J.K.; Kim, J.J.; Weissman, N.J.; Fearnot, N.E.; Park, S.W.; Park, S.J. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries - A serial volumetric intravascular ultrasound analysis from the ASian paclitaxel-eluting stent clinical trial (ASPECT). Circulation, 2003, 107(4), 517-520.
45. Lansky, A.J.; Costa, R.A.; Mintz, G.S.; Tsuchiya, Y.; Midei, M.; Cox, D.A.; O'Shaughnessy, C.; Applegate, R.A.; Cannon, L.A.; Mooney, M.; Farah, A.; Tannenbaum, M.A.; Yakubov, S.; Kereiakes, D.J.; Wong, S.C.; Kaplan, B.; Cristea, E.; Stone, G.W.; Leon, M.B.; Knopf, W.D.; O'Neill, W.W.; DELIVER Clin Trial Investigators Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions - Angiographic follow-up of the DELIVER clinical trial. Circulation, 2004, 109(16), 1948-1954.
46. Grube, E.; Silber, S.; Hauptmann, K.E.; Mueller, R.; Buellesfeld, L.; Gerckens, U.; Russell, M.E. Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxeleluting stent for de novo coronary lesions. Circulation, 2003, 107 (1), 38-42.
47. Colombo, A.; Drzewiecki, J.; Banning, A.; Grube, E.; Hauptmann, K.; Silber, S.; Dudek, D.; Fort, S.; Schiele, F.; Zmudka, K.; Guagliumi, G.; Russell, M.E.; TAXUS II Study Grp. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation, 2003, 108(7), 788-794.
48. Tanabe, K.; Serruys, P.W.; Grube, E.; Smits, P.C.; Selbach, G.; van der Giessen, W.J.; Staberock, M.; de Feyter, P.; Muller, R.; Regar, E.; Degertekin, M.; Ligthart, J.M.R.; Disco, C.; Backx, B.; Russell, M.E. TAXUS III trial - In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation, 2003, 107(4), 559-564.
49. Stone, G.W.; Ellis, S.G.; Cox, D.A.; Hermiller, J.; O'Shaughnessy, C.; Mann, J.T.; Turco, M.; Caputo, R.; Bergin, P.; Greenberg, J.; Popma, J.J.; Russell, M.E.; TAXUS-IV Investigators One-year clinical results with the slow-release, polymer-based, paclitaxeleluting TAXUS Stent the TAXUS-IV trial. Circulation, 2004, 109(16), 1942-1947.
50. Unverdorben, M.; Degenhardt, R.; Wiemer, M.; Horstkotte, D.; Schneider, H.; Nienaber, C.; Bocksch, W.; Gross, M.; Boxberger, M.; Vallbracht, C. The paclitaxel-eluting Coroflex (TM) please stent pilot study (PECOPSI) - The one-year clinical follow-up. Clin. Res. Cardiol., 2007, 96(11), 803-811.
51. Serruys, P.W.; Sianos, G.; Abizaid, A.; Aoki, J.; den Heijer, P.; Bonnier, H.; Smits, P.; McClean, D.; Verheye, S.; Belardi, J.; Condado, J.; Pieper, M.; Garnbone, L.; Bressers, M.; Symons, J.; Sousa, E.; Litvack, F. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform - The paclitaxel in-stent controlled elution study (PISCES). J. Am. Coll. Cardiol., 2005, 46(2), 253-260.
52. Herdeg, C.; Ceisler, T.; Goehring-Frischholz, K.; Zuern, C.; Hartmann, U.; Haase, K.K.; Gawaz, M. Catheter-based local antiproliferative therapy in kissing balloon technique for in-stent stenosis of coronary artery bifurcation lesions. Can. J. Cardiol., 2008, 24(4), 309-311.
53. Fanggiday, J.C.; Stella, P.R.; Guyomi, S.H.; Doevendans, P.A. Safety and efficacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions: The DEBIUT (Drug-Eluting Balloon in BIfurcaton UTrecht) registry. Catheter. Cardiovasc. Interv., 2008, 71(5), 629-635.
54. Scheller, B.; Hehrlein, C.; Bocksch, W.; Rutsch, W.; Haghi, D.; Dietz, U.; Boehm, M.; Speck, U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N. Engl. J. Med., 2006, 355(20), 2113-2124.
55. Kataoka, T.; Grube, E.; Honda, Y.; Morino, Y.; Hur, S.H.; Bonneau, H.N.; Colombo, A.; Di Mario, C.; Guagliumi, G.; Hauptmann, K.E.; Pitney, M.R.; Lansky, A.J.; Stertzer, S.H.; Yock, P.G.; Fitzgerald, P.J.; SCORE Investigators 7-hexanoyltaxoleluting stent for prevention of neointimal growth - An intravascular ultrasound analysis from the study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation, 2002, 106(14), 1788-1793.
56. Liistro, F.; Stankovic, G.; Di Mario, C.; Takagi, T.; Chieffo, A.; Moshiri, S.; Montorfano, M.; Carlino, M.; Briguori, C.; Pagnotta, P.; Albiero, R.; Corvaja, N.; Colombo, A. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis - Immediate and long-term clinical and angiographic outcome. Circulation, 2002, 105(16), 1883-1886.
57. Honda, Y.; Grube, E.; de la Fuente, L.M.; Yock, P.G.; Stertzer, S.H.; Fitzgerald, P.J. Novel drug-delivery stent - Intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation, 2001, 104(4), 380-383.
58. Serruys, P.W.; Ormiston, J.A.; Sianos, G.; Sousa, J.E.; Grube, E.; den Heijer, P.; de Feyter, P.; Buszman, P.; Schomig, A.; Marco, J.; Polonski, L.; Thuesen, L.; Zeiher, A.M.; Bett, J.H.N.; Suttorp, M.J.; Glogar, H.D.; Pitney, M.; Wilkins, G.T.; Whitbourn, R.; Veldhof, S.; Miquel, K.; Johnson, R.; Coleman, L.; Virmani, R.; ACTION Investigators Actinomycin-eluting stent for coronary revascularization - A randomized feasibility and safety study: The ACTION trial. J. Am. Coll. Cardiol., 2004, 44(7), 1363-1367.
59. Kutryk, M.J.B.; Foley, D.P.; van den Brand, M.; Hamburger, J.N.; van der Giessen, W.J.; de Feyter, P.J.; Bruining, N.; Sabate, M.; Serruys, P.W. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis - Results of the randomized investigation by the thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J. Am. Coll. Cardiol., 2002, 39(2), 281-287.
60. Kwok, O.H.; Chow, W.H.; Law, T.C.; Chiu, A.; Ng, W.; Lam, W.F.; Hong, M.K.; Popma, J.J. First human experience with angiopeptin- eluting stent: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Catheter. Cardiovasc. Interv., 2005, 66(4), 541-546.
61. Morice, M.; Serruys, P.W.; Sousa, J.E.; Fajadet, J.; Hayashi, E.B.; Perin, M.; Colombo, A.; Schuler, G.; Barragan, P.; Guagliumi, G.; Molnar, F.; Falotico, R.; RAVEL Study Grp. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med., 2002, 346(23), 1773-1780.
62. Holmes, D.R.; Leon, M.B.; Moses, J.W.; Popma, J.J.; Cutlip, D.; Fitzgerald, P.J.; Brown, C.; Fischell, T.; Wong, S.C.; Midei, M.; Snead, D.; Kuntz, R.E. Analysis of 1-year clinical outcomes in the SIRIUS trial - A randomized trial of a sirolimus-eluting stent ver-sus a standard stent in patients at high risk for coronary restenosis. Circulation, 2004, 109(5), 634-640.
63. Moses, J.W.; Leon, M.B.; Popma, J.J.; Fitzgerald, P.J.; Holmes, D.R.; O'Shaughnessy, C.; Caputo, R.P.; Kereiakes, D.J.; Williams, D.O.; Teirstein, P.S.; Jaeger, J.L.; Kuntz, R.E.; SIRIUS Investigators Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med., 2003, 349(14), 1315-1323.
64. Hausleiter, J.; Kastrati, A.; Wessely, R.; Dibra, A.; Mehilli, J.; Schratzenstaller, T.; Graf, I.; Renke-Gluszko, M.; Behnisch, B.; Dirschinger, J.; Wintermantel, E.; Schomig, A.; Individualizable Drug-Eluting Sten FASTTRACK - Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymerfree, on-site stent coating. Eur. Heart J., 2005, 26(15), 1475-1481.
65. Tamburino, C.; Di Salvo, M.E.; Capodanno, D.; Capranzano, P.; Parisi, R.; Mirabella, F.; Scardaci, F.; Ussia, G.; Galassi, A.R.; Fiscella, D.; Mehran, R.; Dangas, G. Real world safety and efficacy of the janus tacrolimus-eluting stent: long-term clinical outcome and angiographic findings from the tacrolimus-eluting stent (TEST) registry. Catheter. Cardiovasc. Interv., 2009, 73(2), 243-248.
66. Onuma, Y.; Kukreja, N.; Piazza, N.; Eindhoven, J.; Girasis, C.; Schenkeveld, L.; van Domburg, R.; Serruys, P.W.; Interventional cardiologists thora The everolimus-eluting stent in real-world patients 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) Registry. J. Am. Coll. Cardiol., 2009, 54(3), 269-276.
67. Grube, E.; Sonoda, S.; Ikeno, F.; Honda, Y.; Kar, S.; Chan, C.; Gerckens, U.; Lansky, A.J.; Fitzgerald, P.J. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation, 2004, 109(18), 2168-2171.
68. Tsuchida, K.; Garcia-Garcia, H.M.; Ong, A.T.L.; Valgimigli, M.; Aoki, J.; Rademaker, T.A.M.; Morel, M.A.M.; van Es, G.A.; Bruining, N.; Serruys, P.W. Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: Analysis from the SPIRIT FIRST Trial. Catheter. Cardiovasc. Interv., 2006, 67(2), 188-197.
69. Ormiston, J.A.; Serruys, P.W.; Regar, E.; Dudek, D.; Thuesen, L.; Webster, M.W.I.; Onuma, Y.; Garcia-Garcia, H.M.; McGreevy, R.; Veldhof, S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet, 2008, 371(9616), 899-907.
70. Fajadet, J.; Wijns, W.; Laarman, G.; Kuck, K.; Ormiston, J.; Munzel, T.; Popma, J.J.; Fitzgerald, P.J.; Bonan, R.; Kuntz, R.E.; ENDEAVOUR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial. Circulation, 2006, 114(8), 798-806.
71. Abizaid, A.; Lansky, A.J.; Fitzgerald, P.J.; Tanajura, L.F.; Feres, F.; Staico, R.; Mattos, L.; Abizaid, A.; Chaves, A.; Centemero, M.; Sousa, A.G.M.R.; Sousa, J.E.; Zaugg, M.J.; Schwartz, L.B. Percutaneous coronary revascularization using a trilayer metal phosphorylcholine- coated zotarolimus-eluting stent. Am. J. Cardiol., 2007, 99(10), 1403-1408.
72. Liu, X.S.; Huang, Y.M.; Hanet, C.; Vandormael, M.; Legrand, V.; Dens, J.; Vandenbossche, J.L.; Missault, L.; Vrints, C.; De Scheerder, I. Study of antirestenosis with the BiodivYsio dexamethasone- eluting stent (STRIDE): A first-in-human multicenter pilot trial. Catheter. Cardiovasc. Interv., 2003, 60(2), 172-178.
73. Han, S.H.; Ahn, T.H.; Kang, W.C.; Oh, K.J.; Chung, W.; Shin, M.; Koh, K.K.; Choi, I.S.; Shin, E.K. The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: Randomized controlled prospective study. Am. Heart J., 2006, 152(5), 887.
74. Koenig, A.; Leibig, M.; Rieber, J.; Schiele, T.M.; Theisen, K.; Siebert, U.; Gothe, R.M.; Klauss, V. Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: Serial angiographic and sonographic analysis. Am. Heart J., 2007, 153(6), 979.
75. Abizaid, A.; Albertal, M.; Ormiston, J.; Londero, H.; Ruygrok, P.; Seixas, A.C.; Feres, F.; Mattos, L.A.; Staico, R.; Silva, R.L.; Webster, M.; Stewart, J.; Paoletti, F.; Kataoka, T.; Fitzgerald, P.; Sousa, A.; Sousa, J.E. IMPACT trial: Angiographic and intravascular ultrasound observations of the first human experience with mycophenolic acid-eluting polymer Stent system. Catheter. Cardiovasc. Interv., 2005, 66(4), 491-495.
76. De Scheerder, I.; Liu, X.; Huang, Y. Anti-migratory drugs and mechanisms of action. In: Textbook of Interventional Cardiovascular Pharmacology; Kipshidze, N.N.; Fareed, J.; Moses, J.W.; Serruys, P.W., Eds.; Informa Healthcare: London, 2007; pp. 325-337.
77. Jeong, M.H.; Ahn, Y.K.; Cho, J.G.; Park, J.C.; Na, K.J.; Kang, J.C. Successful coronary stent implantation using local nitric oxide donor delivery. J. Interv. Cardiol., 2000, 13(3), 191-195.
78. Laitinen, M.; Hartikainen, J.; Hiltunen, M.O.; Eranen, J.; Kiviniemi, M.; Narvanen, O.; Makinen, K.; Manninen, H.; Syvanne, M.; Martin, J.F.; Laakso, M.; Yla-Herttuala, S. Cathetermediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum. Gene Ther., 2000, 11(2), 263-270.
79. Abizaid, A.; Chaves, A.J.; Leon, M.B.; Hauptmann, K.; Mehran, R.; Lansky, A.J.; Baumbach, W.; Shankar, H.; Muller, R.; Feres, F.; Sousa, A.G.M.R.; Sousa, J.E.; Grube, E. Randomized, doubleblind, multicenter study of the polymer-based 17-beta estradioleluting stent for treatment of native coronary artery lesions: Sixmonth results of the ETHOS I trial. Catheter. Cardiovasc. Interv., 2007, 70(5), 654-660.
80. Abizaid, A.; Albertal, M.; Costa, M.A.; Abizaid, A.S.; Staico, R.; Feres, F.; Mattos, L.A.; Sousa, A.G.M.R.; Moses, J.; Kipshidize, N.; Roubin, G.S.; Mehran, R.; New, G.; Leon, M.B.; Sousa, J.E. First human experience with the 17-beta-estradiol-eluting stent - The Estrogen And Stents To Eliminate Restenosis (EASTER) Trial. J. Am. Coll. Cardiol., 2004, 43(6), 1118-1121.
81. Aoki, J.; Serruys, P.W.; van Beusekom, H.; Ong, A.T.L.; McFadden, E.P.; Sianos, G.; van der Giessen, W.J.; Regar, E.; de Feyter, P.J.; Davis, H.R.; Rowland, S.; Kutryk, M.J.B. Endothelial progenitor cell capture by stents coated with antibody against CD34 - The HEALING-FIM (healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry. J. Am. Coll. Cardiol., 2005, 45(10), 1574-1579.
82. Suzuki, T.; Hayase, M.; Hibi, K.; Hosokawa, H.; Yokoya, K.; Fitzgerald, P.J.; Yock, P.G.; Cooke, J.P.; Suzuki, T.; Yeung, A.C. Effect of local delivery of L-arginine on in-stent restenosis in humans. Am. J. Cardiol., 2002, 89(4), 363-367.
83. Chan, M.Y.; Weitz, J.I.; Merhi, Y.; Harrington, R.A.; Becker, R.C. Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. J. Thromb. Thrombolysis, 2009, 28(3), 366-380.
84. Mani, G.; Feldman, M.D.; Patel, D.; Agrawal, C.M. Coronary stents: A materials perspective. Biomaterials, 2007, 28(9), 1689-1710.
85. Takahashi, H.; Letourneur, D.; Grainger, D.W. Delivery of large biopharmaceuticals from cardiovascular stents: A review. Biomacromolecules, 2007, 8(11), 3281-3293.
86. Ranade, S.V.; Miller, K.M.; Richard, R.E.; Chan, A.K.; Allen, M.J.; Helmus, M.N. Physical characterization of controlled release of paclitaxel from the TAXUS(TM) Express(2TM) drug-eluting stent. J. Biomed. Mater. Res. Part A, 2004, 71A(4), 625-634.
87. Atalar, E.; Haznedaroglu, I.; Aytemir, K.; Aksoyek, S.; Ovunc, K.; Oto, A.; Ozmen, F. Effects of stent coating on platelets and endothelial cells after intracoronary stent implantation. Clin. Cardiol., 2001, 24(2), 159-164.
88. Whelan, D.M.; van der Giessen, W.J.; Krabbendam, S.C.; van Vliet, E.A.; Verdouw, P.D.; Serruys, P.W.; van Beusekom, H.M.M. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart, 2000, 83(3), 338-345.
89. Kuiper, K.K.J.; Robinson, K.A.; Chronos, N.A.F.; Cui, J.H.; Palmer, S.J.; Nordrehaug, J.E. Phosphorylcholine-coated metallic stents in rabbit iliac and porcine coronary arteries. Scand. Cardiovasc. J., 1998, 32(5), 261-268.
90. Lewis, A.L.; Tolhurst, L.A.; Stratford, P.W. Analysis of a phosphorylcholine- based polymer coating on a coronary stent pre- and post-implantation. Biomaterials, 2002, 23(7), 1697-1706.
91. Kipshidze, N.N.; Iversen, P.; Kim, H.S.; Yiazdi, H.; Dangas, G.; Seaborn, R.; New, G.; Tio, F.; Waksman, R.; Mehran, R.; Tsapenko, M.; Stone, G.W.; Roubin, G.S.; Iyer, S.; Leon, M.B.; Moses, J.W. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine- coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter. Cardiovasc. Interv., 2004, 61(4), 518-527.
92. Udipi, K.; Chen, M.; Cheng, P.; Jiang, K.; Judd, D.; Caceres, A.; Melder, R.J.; Wilcox, J.N. Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent. J. Biomed. Mater. Res. Part A, 2008, 85A(4), 1064-1071.
93. Hezi-Yamit, A.; Sullivan, C.; Wong, J.; David, L.; Chen, M.; Cheng, P.; Shumaker, D.; Wilcox, J.N.; Udipi, K. Impact of polymer hydrophilicity on biocompatibility: Implication for DES polymer design. J. Biomed. Mater. Res. Part A, 2009, 90A(1), 133-141.
94. Grube, E.; Buellesfeld, L. BioMatrix (R) Biolimus A9 (R)-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev. Med. Devices, 2006, 3(6), 731-741.
95. Yang, C.M.; Burt, H.A. Drug-eluting stents: Factors governing local pharmacokinetics. Adv. Drug Deliv. Rev., 2006, 58(3), 402-411.
96. Hwang, C.W.; Wu, D.; Edelman, E.R. Physiological transport forces govern drug distribution for stent-based delivery. Circulation, 2001, 104(5), 600-605.
97. Balakrishnan, B.; Dooley, J.F.; Kopia, G.; Edelman, E.R. Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. J. Control. Release, 2007, 123(2), 100-108.
98. Hwang, C.W.; Edelman, E.R. Arterial ultrastructure influences transport of locally delivered drugs. Circ. Res., 2002, 90(7), 826-832.
99. Levin, A.D.; Vukmirovic, N.; Hwang, C.W.; Edelman, E.R. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc. Natl. Acad. Sci. U S A, 2004, 101(25), 9463-9467.
100. Tzafriri, A.R.; Levin, A.D.; Edelman, E.R. Diffusion-limited binding explains binary dose response for local arterial and tumour drug delivery. Cell Prolif., 2009, 42(3), 348-363.
101. Deconinck, E.; Sohier, I.; De Scheerder, I.; Van Den Mooter, G. Pharmaceutical aspects of drug eluting stents. J. Pharm. Sci., 2008, 97(12), 5047-5060.
102. Siepmann, J.; Siepmann, F. Mathematical modeling of drug delivery. Int. J. Pharm., 2008, 364(2), 328-343.
103. Arifin, D.Y.; Lee, L.Y.; Wang, C. Mathematical modeling and simulation of drug release from microspheres: Implications to drug delivery systems. Adv. Drug Deliv. Rev., 2006, 58(12-13), 1274-1325.
104. Kanjickal, D.G.; Lopina, S.T. Modeling of drug release from polymeric delivery systems - A review. Crit. Rev. Ther. Drug Carrier Syst., 2004, 21(5), 345-386.
105. Venkatraman, S.; Boey, F. Release profiles in drug-eluting stents: Issues and uncertainties. J. Control. Release, 2007, 120(3), 149-160.
106. Chatterjee, S.; Pandey, A. Drug eluting stents: Friend or foe? A review of cellular mechanisms behind the effects of paclitaxel and sirolimus eluting Stents. Curr. Drug Metab., 2008, 9(6), 554-566.
107. Urban, P.; Gershlick, A.H.; Guagliumi, G.; Guyon, P.; Lotan, C.; Schofer, J.; Seth, A.; Sousa, J.E.; Wijns, W.; Berge, C.; Deme, M.; Stoll, H.P.; Cypher Investigators. Safety of coronary Sirolimus- Eluting Stents in daily clinical practice - One-year follow-up of the e-cypher registry. Circulation, 2006, 113(11), 1434-1441.
108. Joner, M.; Finn, A.V.; Farb, A.; Mont, E.K.; Kolodgie, F.D.; Ladich, E.; Kutys, R.; Skorija, K.; Gold, H.K.; Virmani, R. Pathology of drug-eluting stents in humans - Delayed healing and late thrombotic risk. J. Am. Coll. Cardiol., 2006, 48(1), 193-202.
109. Caixeta, A.; Leon, M.B.; Lansky, A.J.; Nikolsky, E.; Aoki, J.; Moses, J.W.; Schofer, J.; Morice, M.; Schampaert, E.; Kirtane, A.J.; Popma, J.J.; Parise, H.; Fahy, M.; Mehran, R. 5-Year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus- eluting stents with bare-metal stents. J. Am. Coll. Cardiol., 2009, 54(10), 894-902.
110. Kamath, K.R.; Barry, J.J.; Miller, K.M. The Taxus (TM) drugeluting stent: A new paradigm in controlled drug delivery. Adv. Drug Deliv. Rev., 2006, 58(3), 412-436.
111. Serruys, P.W.; Kutryk, M.J.B.; Ong, A.T.L. Drug therapy - Coronary- artery stents. N. Engl. J. Med., 2006, 354(5), 483-495.
112. Stone, G.W.; Ellis, S.G.; Cox, D.A.; Hermiller, J.; O'Shaughnessy, C.; Mann, J.T.; Turco, M.; Caputo, R.; Bergin, P.; Greenberg, J.; Popma, J.J.; Russell, M.E.; TAXUS-IV Investigators. A polymerbased, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med., 2004, 350(3), 221-231.
113. Dawkins, K.D.; Grube, E.; Guagliumi, G.; Banning, A.P.; Zmudka, K.; Colombo, A.; Thuesen, L.; Hauptman, K.; Marco, J.; Wijns, W.; Popma, J.J.; Koglin, J.; Russell, M.E.; TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial - Support for the use of drug-eluting Stents in contemporary clinical practice. Circulation, 2005, 112(21), 3306-3313.
114. Stone, G.W.; Ellis, S.G.; Cannon, L.; Mann, J.T.; Greenberg, J.D.; Spriggs, D.; O'Shaughnessy, C.D.; DeMaio, S.; Hall, P.; Popma, J.J.; Koglin, J.; Russell, M.E.; TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease - A randomized controlled trial. JAMA, 2005, 294(10), 1215-1223.
115. Schoemig, A.; Dibra, A.; Windecker, S.; Mehilli, J.; de Lezo, J.S.; Kaiser, C.; Park, S.; Goy, J.; Lee, J.; Di Lorenzo, E.; Wu, J.; Jueni, P.; Pfisterer, M.E.; Meier, B.; Kastrati, A. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxeleluting stents in patients with coronary artery disease. J. Am. Coll. Cardiol., 2007, 50(14), 1373-1380.
116. Steffel, J.; Eberli, F.R.; Luescher, T.F.; Tanner, F.C. Drug-eluting stents - what should be improved? Ann. Med., 2008, 40(4), 242-252.
117. Wessely, R.; Schomig, A.; Kastrati, A. Sirolimus and paclitaxel on polymer-based drug-eluting stents - Similar but different. J. Am. Coll. Cardiol., 2006, 47(4), 708-714.
118. Turco, M.A.; Ormiston, J.A.; Popma, J.J.; Mandinov, L.; O'Shaughnessy, C.D.; Mann, T.; McGarry, T.F.; Wu, C.; Chan, C.; Webster, M.W.I.; Hall, J.J.; Mishkel, G.J.; Cannon, L.A.; Baim, D.S.; Koglin, J. Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions - The pivotal TAXUS ATLAS trial. J. Am. Coll. Cardiol., 2007, 49(16), 1676-1683.
119. Meredith, I.T.; Ormiston, J.; Whitbourn, R.; Kay, I.P.; Muller, D.; Bonan, R.; Popma, J.J.; Cutlip, D.E.; Fitzgerald, P.; Prpic, R.; Kuntz, R.E. First-in-human study of the Endeavor ABT-578- eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention, 2005, 1(2), 157-164.
120. Chen, Y.; Smith, M.L.; Sheets, M.; Ballaron, S.; Trevillyan, J.M.; Burke, S.E.; Rosenberg, T.; Henry, C.; Wagner, R.; Bauch, J.; Marsh, K.; Fey, T.A.; Hsieh, G.; Gauvin, D.; Mollison, K.W.; Carter, G.W.; Djuric, S.W. Zotarolimus, a novel Sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. J. Cardiovasc. Pharmacol., 2007, 49(4), 228-235.
121. Sakurai, R.; Hongo, Y.; Yamasaki, M.; Honda, Y.; Bonneau, H.N.; Yock, P.G.; Cutlip, D.; Popma, J.J.; Zimetbaum, P.; Fajadet, J.; Kuntz, R.E.; Wijns, W.; Fitzgerald, P.J.; ENDEAVOR II Trial Invest. Detailed intravascular ultrasound analysis of Zotarolimuseluting phosphorylcholine-coated cobalt-chromium alloy stent in de Novo Coronary lesions (results from the ENDEAVOR II trial). Am. J. Cardiol., 2007, 100(5), 818-823.
122. Miyazawa, A.; Ako, J.; Hongo, Y.; Hur, S.; Tsujino, I.; Courtney, B.K.; Hassan, A.H.M.; Kandzari, D.E.; Honda, Y.; Fitzgerald, P.J.; ENDEAVOR III Investigators. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: Intravascular ultrasound results from ENDEAVOR III. Am. Heart J., 2008, 155(1), 108-113.
123. Kandzari, D.E.; Leon, M.B.; Popma, J.J.; Fitzgerald, P.J.; O'Shaughnessy, C.; Ball, M.W.; Turco, M.; Applegate, R.J.; Gurbel, P.A.; Midei, M.G.; Badre, S.S.; Mauri, L.; Thompson, K.P.; LeNarz, L.A.; Kuntz, R.E.; ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease - A randomized controlled trial. J. Am. Coll. Cardiol., 2006, 48(12), 2440-2447.
124. Byrne, R.A.; Sarafoff, N.; Kastrati, A.; Schoemig, A. Drug-Eluting stents in percutaneous coronary intervention a benefit-risk assessment. Drug Saf., 2009, 32(9), 749-770.
125. Meredith, I.T.; Worthley, S.; Whitbourn, R.; Walters, D.; Popma, J.; Cutlip, D.; Fitzgerald, P. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroInterv, 2007, 3(1), 50-53.
126. Kukreja, N.; Onuma, Y.; Serruys, P.W. Xience V (TM) everolimus- eluting coronary stent. Expert Rev. Med. Devices, 2009, 6(3), 219-229.
127. Stone, G.W.; Midei, M.; Newman, W.; Sanz, M.; Hermiller, J.B.; Williams, J.; Farhat, N.; Mahaffey, K.W.; Cutlip, D.E.; Fitzgerald, P.J.; Sood, P.; Su, X.; Lansky, A.J.; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease - A randomized trial. JAMA, 2008, 299(16), 1903-1913.
128. Lewis, A.L.; Vick, T.A.; Collias, A.C.M.; Hughes, L.G.; Palmer, R.R.; Leppard, S.W.; Furze, J.D.; Taylor, A.S.; Stratford, P.W. Phosphorylcholine-based polymer coatings for stent drug delivery. J. Mater. Sci. -Mater. Med., 2001, 12(10-12), 865-870.
129. Sharif, F.; Hynes, S.O.; McMahon, J.; Cooney, R.; Conroy, S.; Dockery, P.; Duffy, G.; Daly, K.; Crowley, J.; Bartlett, J.S.; O'Brien, T. Gene-eluting stents: Comparison of adenoviral and adeno-associated viral gene delivery to the blood vessel wall in vivo. Hum. Gene Ther., 2006, 17(7), 741-750.
130. Johnson, T.W.; Wu, Y.X.; Herdeg, C.; Baumbach, A.; Newby, A.C.; Karsch, K.R.; Oberhoff, M. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries. Arterioscler. Thromb. Vasc. Biol., 2005, 25(4), 754-759.
131. Walter, D.H.; Cejna, M.; Diaz-Sandoval, L.; Willis, S.; Kirkwood, L.; Stratford, P.W.; Tietz, A.B.; Kirchmair, R.; Silver, M.; Curry, C.; Wecker, A.; Yoon, Y.S.; Heidenreich, R.; Hanley, A.; Kearney, M.; Tio, F.O.; Kuenzler, P.; Isner, J.M.; Losordo, D.W. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents - An alternative strategy for inhibition of restenosis. Circulation, 2004, 110(1), 36-45.
132. De Labriolle, A.; Pakala, R.; Bonello, L.; Lemesle, G.; Scheinowitz, M.; Waksman, R. Paclitaxel-Eluting balloon: from bench to bed. Catheter. Cardiovasc. Interv., 2009, 73(5), 643-652.
133. Wolinsky, H.; Thung, S.N. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J. Am. Coll. Cardiol., 1990, 15(2), 475-481.
134. Lincoff, A.M.; Topol, E.J.; Ellis, S.G. Local-Drug delivery for the prevention of restenosis - fact, fancy, and future. Circulation, 1994, 90(4), 2070-2084.
135. Groh, W.C.; Kurnik, P.B.; Matthai, W.H.; Untereker, W.J. Initial experience with an intracoronary flow support device providing localized drug infusion - the scimed dispatch catheter. Cathet. Cardiovasc. Diagn., 1995, 36(1), 67-73.
136. Cremers, B.; Speck, U.; Kaufels, N.; Mahnkopf, D.; Kuehler, M.; Boehm, M.; Scheller, B. Drug-eluting balloon: Very short-term exposure and overlapping. Thromb. Haemost., 2009, 101(1), 201-206.
137. Unverdorben, M.; Vallbracht, C.; Cremers, B.; Heuer, H.; Hengstenberg, C.; Maikowski, C.; Werner, G.S.; Antoni, D.; Kleber, F.X.; Bocksch, W.; Leschke, M.; Ackermann, H.; Boxberger, M.; Speck, U.; Degenhardt, R.; Scheller, B. Paclitaxel-Coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation, 2009, 119(23), 2986-2994.
138. Herdeg, C.; Goehring-Frischholz, K.; Zuern, C.; Geisler, T.; Hartmann, U.; Hoevelborn, T.; Haase, K.K.; Gawaz, M. Local catheterbased delivery of antithrombotic or antiproliferative drugs: A new concept for prevention of restenosis. Thromb. Res., 2008, 123(2), 236-243.
139. Muldowney, James A.S.; Stringham, J.R.; Levy, S.E.; Gleaves, L.A.; Eren, M.; Piana, R.N.; Vaughan, D.E. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression - A potential prothrombotic mechanism of drug-eluting stents. Arterioscler. Thromb. Vasc. Biol., 2007, 27(2), 400-406.
140. Steffel, J.; Latini, R.A.; Akhmedov, A.; Zimmermann, D.; Zimmerling, P.; Luscher, T.F.; Tanner, F.C. Rapamycin, but not FK-506, increases endothelial tissue factor expression - Implications for drug-eluting stent design. Circulation, 2005, 112(13), 2002-2011.
141. Staehli, B.E.; Camici, G.G.; Steffel, J.; Akhmedov, A.; Shojaati, K.; Graber, M.; Luescher, T.F.; Tanner, F.C. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ. Res., 2006, 99(2), 149-155.
142. Grines, C.L.; Bonow, R.O.; Casey, D.E., Jr.; Gardner, T.J.; Lockhart, P.B.; Moliterno, D.J.; O'Gara, P.; Whitlow, P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents - A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation, 2007, 115(6), 813-818.
143. Daemen, J.; Wenaweser, P.; Tsuchida, K.; Abrecht, L.; Sophia, V.; Morger, C.; Kukreja, N.; Jueni, P.; Sianos, G.; Hellige, G.; van Domburg, R.T.; Hess, O.M.; Boersma, E.; Meier, B.; Windecker, S.; Serruys, P.W. Early and late coronary stent thrombosis of sirolimus- eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet, 2007, 369(9562), 667-678.
144. Byrne, R.A.; Kastrati, A.; Tiroch, K.; Schulz, S.; Pache, J.; Pinieck, S.; Massberg, S.; Seyfarth, M.; Laugwitz, K.; Birkmeier, K.A.; Schoemig, A.; Mehilli, J.; ISAR-TEST-2 Investigators. 2-Year Clinical and Angiographic Outcomes From a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents Versus Polymer-Based Cypher and Endeavor, Drug-Eluting Stents. J. Am. Coll. Cardiol., 2010, 55(23), 2536-2543.
145. Virmani, R.; Farb, A.; Guagliumi, G.; Kolodgie, F.D. Drug-eluting stents: caution and concerns for long-term outcome. Coron. Artery Dis., 2004, 15(6), 313-318.
146. Virmani, R.; Guagliumi, G.; Farb, A.; Musumeci, G.; Grieco, N.; Motta, T.; Mihalcsik, L.; Tespili, M.; Valsecchi, O.; Kolodgie, F.D. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent should we be cautious? Circulation, 2004, 109(6), 701-705.
147. Nebeker, J.R.; Virmani, R.; Bennett, C.L.; Hoffman, J.M.; Samore, M.H.; Alvarez, J.; Davidson, C.J.; McKoy, J.M.; Raisch, D.W.; Whisenant, B.K.; Yarnold, P.R.; Belknap, S.M.; West, D.P.; Gage, J.E.; Morse, R.E.; Gligoric, G.; Davidson, L.; Feldman, M.D. Hypersensitivity cases associated with drug-eluting coronary stents - A review of available cases from the research on adverse drug events and reports (RADAR) project. J. Am. Coll. Cardiol., 2006, 47(1), 175-181.
148. Kastrati, A.; Mehilli, J.; Dirschinger, J.; Dotzer, F.; Schuhlen, H.; Neumann, F.J.; Fleckenstein, M.; Pfafferott, C.; Seyfarth, M.; Schomig, A. Intracoronary stenting and angiographic results - Strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation, 2001, 103(23), 2816-2821.
149. Ramcharitar, S.; Serruys, P.W. Fully biodegradable coronary stents progress to date. Am. J. Cardiovasc. Drugs, 2008, 8(5), 305-314.
150. Zilberman, M.; Eberhart, R.C. Drug-eluting bioresorbable stents for various applications. Annu. Rev. Biomed. Eng., 2006, 8, 153-180.
151. Tsuji, T.; Tamai, H.; Igaki, K.; Kyo, E.; Kosuga, K.; Hata, T.; Okada, M.; Nakamura, T.; Fujita, S.; Takeda, S.; Motohara, S.; Uehata, H. Biodegradable stents as a platform to drug loading. Int. J. Cardiovasc. Interve., 2003, 5(1), 13-16.
152. Serruys, P.W.; Ormiston, J.A.; Onuma, Y.; Regar, E.; Gonzalo, N.; Garcia-Garcia, H.M.; Nieman, K.; Bruining, N.; Dorange, C.; Miquel-Hebert, K.; Veldhof, S.; Webster, M.; Thuesen, L.; Dudek, D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet, 2009, 373(9667), 897-910.
153. Vogt, F.; Stein, A.; Rettemeier, G.; Krott, N.; Hoffmann, R.; vom Dahl, J.; Bosserhoff, A.K.; Michaeli, W.; Hanrath, P.; Weber, C.; Blindt, R. Long-term assessment of a novel biodegradable paclitaxel- eluting coronary polylactide stent. Eur. Heart J., 2004, 25(15), 1330-1340.
154. Wykrzykowska, J.J.; Onuma, Y.; Serruys, P.W. Advances in stent drug delivery: the future is in bioabsorbable stents. Expert Opin. Drug Deliv., 2009, 6(2), 113-126.
155. Uurto, I.; Mikkonen, J.; Parkkinen, J.; Keski-Nisula, L.; Nevalainen, T.; Kellomaki, M.; Tormala, P.; Salenius, J.P. Drugeluting biodegradable poly-D/L-lactic acid vascular stents: An experimental pilot study. J. Endovasc. Ther., 2005, 12(3), 371-379.
156. Mikkonen, J.; Uurto, I.; Isotalo, T.; Kotsar, A.; Tammela, T.L.J.; Talja, M.; Salenius, J.-.; Tormala, P.; Kellomaki, M. Drug-eluting bioabsorbable stents - An in vitro study. Acta Biomater., 2009, 5(8), 2894-2900.
157. Chen, M.; Chang, Y.; Liu, C.; Lai, W.; Peng, S.; Hung, Y.; Tsai, H.; Sung, H. The characteristics and in vivo suppression of neointimal formation with sirolimus-eluting polymeric stents. Biomaterials, 2009, 30(1), 79-88.
158. Chen, M.; Liu, C.; Tsai, H.; Lai, W.; Chang, Y.; Sung, H. Mechanical properties, drug eluting characteristics and in vivo performance of a genipin-crosslinked chitosan polymeric stent. Biomaterials, 2009, 30(29), 5560-5571.
159. Lendlein, A.; Langer, R. Biodegradable, elastic shape-memory polymers for potential biomedical applications. Science, 2002, 296(5573), 1673-1676.
160. Wischke, C.; Neffe, A.T.; Steuer, S.; Lendlein, A. Evaluation of a degradable shape-memory polymer network as matrix for controlled drug release. J. Control. Release, 2009, 138(3), 243-250.
161. Finkelstein, A.; McClean, D.; Kar, S.; Takizawa, K.; Varghese, K.; Baek, N.; Park, K.; Fishbein, M.C.; Makkar, R.; Litvack, F.; Eigler, N.L. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation, 2003, 107(5), 777-784.
162. Krucoff, M.W.; Kereiakes, D.J.; Petersen, J.L.; Mehran, R.; Hasselblad, V.; Lansky, A.J.; Fitzgerald, P.J.; Garg, J.; Turco, M.A.; Simonton, Charles A III; Verheye, S.; Dubois, C.L.; Gammon, R.; Batchelor, W.B.; O'Shaughnessy, C.D.; Hermiller, J.B., Jr.; Schofer, J.; Buchbinder, M.; Wijns, W.; COSTAR II Investigators Grp. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease. J. Am. Coll. Cardiol., 2008, 51(16), 1543-1552.
163. Ya-ling, H.; Shou-li, W.; Quah-min, J.; Hai-bo, Y.; Bin, W.; Yingyan, M.; Bo, L.; Geng, W. Midterm outcomes of prospective, randomized, single-center study of the Janus tacrolimus-eluting stent for treatment of native coronary artery lesions. Chin. Med. J., 2007, 120(7), 552-556.
164. Byrne, R.A.; Kastrati, A.; Kufner, S.; Massberg, S.; Birkmeier, K.A.; Laugwitz, K.; Schulz, S.; Pache, J.; Fusaro, M.; Seyfarth, M.; Schoemig, A.; Mehilli, J.; ISAR-TEST-4 Investigators. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISARTEST- 4) Trial. Eur. Heart J., 2009, 30(20), 2441-2449.
165. Windecker, S.; Serruys, P.W.; Wandel, S.; Buszman, P.; Trznadel, S.; Linke, A.; Lenk, K.; Ischinger, T.; Klauss, V.; Eberli, F.; Corti, R.; Wijns, W.; Morice, M.C.; di Mario, C.; Davies, S.; van Geuns, R.; Eerdmans, P.; van Es, G.; Meier, B.; Jueni, P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet, 2008, 372(9644), 1163-1173.
166. Hai-bo, L.; Bo, X.; Yue-jin, Y.; Yang, W.; Xue-wen, Q.; Min, Y.; Yong-jian, W.; Jin-qing, Y.; Jue, C.; Shi-jie, Y.; Jun, D.; Wei-hua, M.; Jian-jun, L.; Shu-bin, Q.; Ji-lin, C.; Wei, L.; Run-lin, G. Longterm clinical outcomes after bioabsorbable polymer- and durable polymer-based sirolimus-eluting stents implantation: two-year follow- up results from a large single-center database. Chin. Med. J., 2009, 122(6), 681-686.
167. Chen, M.C.; Liang, H.F.; Chiu, Y.L.; Chang, Y.; Wei, H.J.; Sung, H.W. A novel drug-eluting stent spray-coated with multi-layers of collagen and sirolimus. J. Control. Release, 2005, 108(1), 178-189.
168. Wang, X.; Zhang, X.; Castellot, J.; Herman, I.; Iafrati, M.; Kaplan, D.L. Controlled release from multilayer silk biomaterial coatings to modulate vascular cell responses. Biomaterials, 2008, 29(7), 894-903.
169. Choi, J.; Konno, T.; Takai, M.; Ishihara, K. Controlled drug release from multilayered phospholipid polymer hydrogel on titanium alloy surface. Biomaterials, 2009, 30(28), 5201-5208.
170. Jewell, C.M.; Zhang, J.; Fredin, N.J.; Wolff, M.R.; Hacker, T.A.; Lynn, D.M. Release of plasmid DNA from intravascular stents coated with ultrathin multilayered polyelectrolyte films. Biomacromolecules, 2006, 7(9), 2483-2491.
171. Meng, S.; Liu, Z.; Shen, L.; Guo, Z.; Chou, L.L.; Zhong, W.; Du, Q.; Ge, J. The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system. Biomaterials, 2009, 30(12), 2276-2283.
172. Nakayama, Y.; Masuda, T. Development of a polymeric matrix metalloproteinase inhibitor as a bioactive stent coating material for prevention of restenosis. J. Biomed. Mater. Res. Part B, 2007, 80B(1), 260-267.
173. Ikuta, K.; Mori, T.; Yamamoto, T.; Niidome, T.; Shimokawa, H.; Katayama, Y. Development of polymeric drug delivery system for recognizing vascular endothelial dysfunction. Bioorg. Med. Chem., 2008, 16(6), 2811-2818.
174. Labhasetwar, V.; Song, C.X.; Levy, R.J. Nanoparticle drug delivery system for restenosis. Adv. Drug Deliv. Rev., 1997, 24(1), 63-85.
175. Westedt, U.; Kalinowski, M.; Wittmar, M.; Merdan, T.; Unger, F.; Fuchs, J.; Schaeller, S.; Bakowsky, U.; Kissel, T. Poly(vinyl alcohol)- graft-poly(lactide-co-glycolide) nanoparticles for local delivery of paclitaxel for restenosis treatment. J. Control. Release, 2007, 119(1), 41-51.
176. Zou, W.; Cao, G.; Xi, Y.; Zhang, N. New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles. Drug Deliv., 2009, 16(1), 15-23.
177. Mei, L.; Sun, H.; Song, C. Local delivery of modified paclitaxelloaded poly(epsilon-caprolactone)/pluronic F68 nanoparticles for long-term inhibition of hyperplasia. J. Pharm. Sci., 2009, 98(6), 2040-2050.
178. Sasaki, T.; Kuzuya, M.; Cheng, X.W.; Nakamura, K.; Tamaya- Mori, N.; Maeda, K.; Kanda, S.; Koike, T.; Sato, K.; Iguchi, A. A novel model of occlusive thrombus formation in mice. Lab. Invest., 2004, 84(11), 1526-1532.
179. Lee, H.J.; Choi, S.H.; Nah, M.H.; Lim, J.O.; Lee, I.K. Fabrication of an alpha-lipoic acid-eluting poly-(D,L-lactide-co-caprolactone) cuff for the inhibition of neointimal formation. Exp. Mol. Med., 2009, 41(1), 25-32.
180. Pires, N.M.M.; van der Hoeven, B.L.; de Vries, M.R.; Havekes, L.M.; van Vlijmen, B.J.; Hennink, W.E.; Quax, P.H.A.; Jukema, J.W. Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff. Biomaterials, 2005, 26(26), 5386-5394.
181. Livnat, M.; Beyar, R.; Seliktar, D. Endoluminal hydrogel films made of alginate and polyethylene glycol: Physical characteristics and drug-eluting properties. J. Biomed. Mater. Res. Part A, 2005, 75A(3), 710-722.
182. Nakayama, Y.; Nishi, S.; Ueda-Ishibashi, H.; Matsuda, T. Fabrication of micropored elastomeric film-covered stents and acute-phase performances. J. Biomed. Mater. Res. Part A, 2003, 64A(1), 52-61.
183. Yeung, A.C.; Tsao, P. Statin therapy - Beyond cholesterol lowering and antiinflammatory effects. Circulation, 2002, 105(25), 2937-2938.
184. Miyauchi, K.; Kasai, T.; Yokayama, T.; Aihara, K.; Kurata, T.; Kajimoto, K.; Okazaki, S.; Ishiyama, H.; Daida, H. Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model. Circ. J., 2008, 72(5), 832-838.
185. Stefanadis, C.; Toutouzas, K.; Stefanadi, E.; Lazaris, A.; Patsouris, E.; Kipshidze, N. Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: An experimental study. Atherosclerosis, 2007, 195(2), 269-276.
186. Blindt, R.; Vogt, F.; Astafieva, I.; Fach, C.; Hristov, M.; Krott, N.; Seitz, B.; Kapurniotu, A.; Kwok, C.; Dewor, M.; Bosserhoff, A.K.; Bernhagen, J.; Hanrath, P.; Hofmann, R.; Weber, C. A novel drugeluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J. Am. Coll. Cardiol., 2006, 47(9), 1786-1795.
187. Jacob, S.W.; de la Torre, J.C. Pharmacology of dimethyl sulfoxide in cardiac and CNS damage. Pharmacol. Rep., 2009, 61(2), 225-235.
188. Camici, G.G.; Steffel, J.; Akhmedov, A.; Schafer, N.; Baldinger, J.; Schulz, U.; Shojaati, K.; Matter, C.M.; Yang, Z.; Luescher, T.F.; Tanner, F.C. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation - A potential treatment strategy for drug-eluting stents. Circulation, 2006, 114(14), 1512-1521.
189. Deuse, T.; Erben, R.G.; Ikeno, F.; Behnisch, B.; Boeger, R.; Connolly, A.J.; Reichenspurner, H.; Bergow, C.; Pelletier, M.P.; Robbins, R.C.; Schrepfer, S. Introducing the first polymer-free leflunomide eluting stent. Atherosclerosis, 2008, 200(1), 126-134.
190. Yang, J.; Zeng, Y.; Li, Y.; Song, C.; Zhu, W.; Guan, H.; Li, X. Intravascular site-specific delivery of a therapeutic antisense for the inhibition of restenosis. Eur. J. Pharm. Sci., 2008, 35(5), 427-434.
191. Geraldes, P.; Geoffroy, P.; Cloutier, I.; Sirois, M.G.; Tanguay, J. Local delivery of 17-beta-estradiol modulates collagen content in coronary porcine arteries after PTCA and stent implantation. J. Vasc. Res., 2008, 45(6), 503-511.
192. Hans, C.P.; Zerfaoui, M.; Naura, A.S.; Troxclair, D.; Strong, J.P.; Matrougui, K.; Boulares, A.H. Thieno[2,3-c]Isoquinolin-5-one, a potent poly(ADP-Ribose) polymerase inhibitor, promotes atherosclerotic plaque regression in high-fat diet-fed apolipoprotein edeficient mice: effects on inflammatory markers and lipid content. J. Pharmacol. Exp. Ther., 2009, 329(1), 150-158.
193. Nash, P.; Whitty, A.; Handwerker, J.; Macen, J.; McFadden, G. Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1. J. Biol. Chem., 1998, 273(33), 20982-20991.
194. Richardson, J.; Viswanathan, K.; Lucas, A. Serpins, the vasculature, and viral therapeutics. Front. Biosci., 2006, 11, 1042-1056.
195. Dai, E.; Guan, H.Y.; Liu, L.Y.; Little, S.; McFadden, G.; Vaziri, S.; Cao, H.N.; Ivanova, I.A.; Bocksch, L.; Lucas, A. Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury. J. Biol. Chem., 2003, 278(20), 18563-18572.
196. Lucas, A.; Dai, E.B.; Liu, L.Y.; Guan, H.Y.; Nash, P.; McFadden, G.; Miller, L. Transplant vasculopathy: Viral anti-inflammatory serpin regulation of atherogenesis. J. Heart Lung Transplant., 2000, 19(11), 1029-1038.
197. Lucas, A.; Liu, L.Y.; Macen, J.; Nash, P.; Dai, E.; Stewart, M.; Graham, K.; Etches, W.; Boshkov, L.; Nation, P.N.; Humen, D.; Hobman, M.L.; McFadden, G. Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation, 1996, 94(11), 2890-2900.
198. Miller, L.W.; Dai, E.; Nash, P.; Liu, L.Y.; Icton, C.; Klironomos, D.; Fan, L.; Nation, P.N.; Zhong, R.; McFadden, G.; Lucas, A. Inhibition of transplant vasculopathy in a rat aortic allograft model after infusion of anti-inflammatory viral serpin. Circulation, 2000, 101(13), 1598-1605.
199. Bot, I.; von der Thusen, J.H.; Donners, M.M.P.C.; Lucas, A.; Fekkes, M.L.; de Jager, S.C.A.; Kuiper, J.; Daemen, M.J.A.P.; van Berkel, T.J.C.; Heeneman, S.; Biessen, E.A.L. Serine protease inhibitor Serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE(-/-) mice. Circ. Res., 2003, 93(5), 464-471.
200. Lucas, A.; Liu, L.; Dai, E.; Bot, I.; Viswanathan, K.; Munuswamy- Ramunujam, G.; Davids, J.A.; Bartee, M.Y.; Richardson, J.; Christov, A.; Wang, H.; Macaulay, C.; Poznansky, M.; Zhong, R.; Miller, L.; Biessen, E.; Richardson, M.; Sullivan, C.; Moyer, R.; Hatton, M.; Lomas, D.A.; McFadden, G. The Serpin Saga; Development of a New Class of Virus Derived Anti-Inflammatory Protein Immunotherapeutics. Adv. Exp. Med. Biol., 2009, 666, 132-156.
201. Tardif, J.; L'Allier, P.; Gregoire, J.; Ibrahim, R.; McFadden, G.; Kostuk, W.J.; Knudtson, M.L.; Labinaz, M.; Waksman, R.; Pepine, C.J.; Macaulay, C.; Lucas, A. Viral anti-inflammatory treatment of unstable coronary syndromes: The VT-111 acute coronary syndrome trial. Circulation, 2009, 120(18), S1145.
202. Viswanathan, K.; Liu, L.Y.; Vaziri, S.; Dai, E.; Richardson, J.; Togonu-Bickersteth, B.; Vatsya, P.; Christov, A.; Lucas, A.R. Myxoma viral serpin, Serp-I, a unique interceptor of coagulation and innate immune pathways. Thromb. Haemost., 2006, 95(3), 499-510.
203. Kobsa, S.; Saltzman, W.M. Bioengineering approaches to controlled protein delivery. Pediatr. Res., 2008, 63(5), 513-519.
204. Wan, W.K.; Campbell, G.; Zhang, Z.F.; Hui, A.J.; Boughner, D.R. Optimizing the tensile properties of polyvinyl alcohol hydrogel for the construction of a bioprosthetic heart valve stent. J. Biomed. Mater. Res., 2002, 63(6), 854-861.
205. Yang, L. Poly(vinyl alcohol) Hydrogel-Based Controlled Release System for Wound Treatment, PhD Thesis, The University of Western Ontario: London, Ontario, Canada, 2008.
206. Millon, L.E.; Nieh, M.; Hutter, J.L.; Wan, W. SANS characterization of an anisotropic poly(vinyl alcohol) hydrogel with vascular applications. Macromolecules, 2007, 40(10), 3655-3662.
207. Kanaya, T.; Ohkura, M.; Kaji, K.; Furusaka, M.; Misawa, M. Structure of poly(vinyl alcohol) gels studied by wide-angle and smallangle neutron-scattering. Macromolecules, 1994, 27(20), 5609-5615.
208. Kanaya, T.; Ohkura, M.; Takeshita, H.; Kaji, K.; Furusaka, M.; Yamaoka, H.; Wignall, G.D. Gelation process of poly(vinyl alcohol) as studied by small-angle neutron and light-scattering. Macromolecules, 1995, 28(9), 3168-3174.
209. Fergg, F.; Keil, F.J.; Quader, H. Investigations of the microscopic structure of poly(vinyl alcohol) hydrogels by confocal laser scanning microscopy. Colloid Polym. Sci., 2001, 279(1), 61-67.
210. Ricciardi, R.; Auriemma, F.; De Rosa, C.; Laupretre, F. X-ray diffraction analysis of poly(vinyl alcohol) hydrogels, obtained by freezing and thawing techniques. Macromolecules, 2004, 37(5), 1921-1927.
211. Mongia, N.K.; Anseth, K.S.; Peppas, N.A. Mucoadhesive poly(vinyl alcohol) hydrogels produced by freezing/thawing processes: applications in the development of wound healing systems. J. Biomater. Sci. Polym. Ed., 1996, 7(12), 1055-1064.
212. Ricciardi, R.; Mangiapia, G.; Lo Celso, F.; Paduano, L.; Triolo, R.; Auriemma, F.; De Rosa, C.; Laupretre, F. Structural organization of poly(vinyl alcohol) hydrogels obtained by freezing and thawing techniques: A SANS study. Chem. Mat., 2005, 17(5), 1183-1189.
213. Ficek, B.J.; Peppas, N.A. Novel Preparation of Poly(vinyl Alcohol) microparticles without cross-linking agent for controlled drugdelivery of proteins. J. Control. Release, 1993, 27(3), 259-264.
214. Peppas, N.A.; Scott, J.E. Controlled release from poly(vinyl alcohol) gels prepared by freezing-thawing processes. J. Control. Release, 1992, 18(2), 95-100.
215. Li, J.K.; Wang, N.; Wu, X.S. Poly(vinyl alcohol) nanoparticles prepared by freezing-thawing process for protein/peptide drug delivery. J. Control. Release, 1998, 56(1-3), 117-126.